BioSpace News Archive

Axiom Real-Time Metrics (“Axiom”), the premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at DIA 2022 June 20-22 in Chicago, Il.

The global heparin market size is expected to reach USD 7.55 Billion in 2028 at a CAGR of 1.4% during the forecast period, according to the latest report by Reports and Data.

The global stem cell manufacturing market size is expected to reach USD 28.85 billion by 2028, registering a CAGR of 6.8% over the forecast period, according to the latest report by Reports and Data.

Orphazyme A/S, hereby provides notice to holders of American Depositary Shares evidenced by American Depositary Receipts representing deposited common shares of the Company regarding termination of the Deposit Agreement dated September 28, 2020 among the Company, The Bank of New York Mellon, as depositary, and Owners and ADR Holders.

Human Longevity, Inc., built by the pioneers of the human genome sequencing effort, and Freedom Acquisition I Corporation, a publicly traded special purpose acquisition company, announced that they have signed a non-binding letter of intent for a proposed business combination that would result in HLI becoming a publicly listed company.

Hear+Hi, a subsidiary of California-based micro-electromechanical systems microphones and voice interface software developer GMEMS Technologies, has recently launched its latest assistive hearing device, Acuity Duo True Wireless Earbuds.

Therorna Inc., a China-based biotech company specialized in the development of cutting-edge circular RNA (or circRNA) technology-based new vaccines and therapies, announced the completion of a US$42 million Series A financing round.

DermaSensor Inc., a health technology company designing non-invasive tools to better equip primary care physicians (PCPs) to detect skin cancer, has successfully met all primary endpoints for their two FDA pivotal studies.

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, announces today that it will be present, alongside with its collaborators, eight presentations at this year’s International Liver Congress (ILC) in London, June 22-25, 2022.

XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer. Enrollment in the Phase II portion is commencing immediately.